Results 1 to 10 of about 79,611 (233)

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells [PDF]

Iranian Journal of Basic Medical Sciences, 2023
Objective(s): Intolerable side effects and resistance to chemotherapeutic drugs have encouraged scientists to develop new methods of drug combinations with fewer complications.
Rohollah Kamyabi, Alireza Jahandideh, Negar Panahi, Samad Mohammadnejad   +3 more
doaj   +1 more source

Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells

Hematology, 2022
Objective: Imatinib mesylate (IM), a tyrosine kinase inhibitor, exhibits clinically prominent effects against chronic myeloid leukemia (CML); however, a few patients have shown resistance to IM treatment, resulting in disease progression.
Jiangzhao Zhang, Min Zhang, Yan Liang, Min Liu, Zhiping Huang   +4 more
doaj   +1 more source

K562 human erythroleukemia cells demonstrate commitment [PDF]

Blood, 1985
Commitment, ie, the decision to express a differentiated phenotype and to terminate proliferation irreversibly in the absence of inducer, was investigated in K562 human erythroleukemia cells. Cells were cultured for 0, 1, 2, 3, or 4 days with inducer and then plated in medium containing methylcellulose without inducer.
P T, Rowley, B M, Ohlsson-Wilhelm, B A, Farley   +2 more
openaire   +3 more sources

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells [PDF]

International Journal of Biological Sciences, 2016
Chronic myelogenous leukemia (CML) is a malignant hematological disorder mainly caused by the Bcr-Abl tyrosine kinase. While Bcr-Abl inhibitors including Imatinib showed antitumor efficacy on many CML patients, resistance was frequently reported in recent years. Therefore, novel drugs for CML are still expected.
Zhou, Qianxiang, Chen, Yali, Chen, Xi, Zhao, Wennan, Zhong, Yuxu, Wang, Ran, Jin, Meihua, Qiu, Yuling, Kong, Dexin   +8 more
openaire   +2 more sources

Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy [PDF]

Toxicology Mechanisms and Methods, 2012
Arsenic trioxide (As(2)O(3)) has been reported to have potent antitumor effects in vitro and in vivo by inducing cell death via cell cycle arrest and apoptosis in leukemia cells, but the mechanisms of As(2)O(3)-mediated cell death are not fully understood.
Juan, Cheng, Hu-Lai, Wei, Jing, Chen, Bei, Xie   +3 more
openaire   +2 more sources

Evaluation of Cytotoxicity, Cell Cycle, and Apoptosis Induction of Methyl Thiosemicarbazone Complex with Copper on K562 Cell Line [PDF]

Journal of Research in Applied and Basic Medical Sciences, 2022
Background & Aims:  Chronic human myeloid leukemia (CML) is caused by mutations and changes in stem cells. This study aimed to investigate the toxicity, apoptosis, and cell cycle of thiosemicarbazone complex with copper on the human chronic myelogenous ...
Neda Kazemi Motlagh, Saeed Hesami Tackallou, Majid Mahdavi, Mahdi Hosseinzadeh   +3 more
doaj  

Modulation of p-glycoprotein-mediated efflux pirarubicin in living multidrug-resistant K562/Dox cell lines by 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid via impairment of the cellular energetic state

Toxicology Reports, 2022
The objective was to investigate the effect of 4-hydroxybenzoic acid (4-HBA) and 4-hydroxy-3-methoxybenzoic acid (Vanillic acid, VA) on p-glycoprotein (P-gp) activity in multidrug-resistant K562/Dox cancer cells.
Ohnmar Myint, Sakornniya Wattanapongpitak, Suchart Kothan, Chatchanok Udomtanakunchai, Singkome Tima, Montree Tungjai   +5 more
doaj   +1 more source

Proteomic Analysis of Quercetin-Treated K562 Cells [PDF]

International Journal of Molecular Sciences, 2019
Among natural products under investigation for their additive potential in cancer prevention and treatment, the flavonoid quercetin has received attention for its effects on the cell cycle arrest and apoptosis. In the past, we addressed this issue in K562 cells, a cellular model of the human chronic myeloid leukemia.
Brisdelli F., Di Francesco L., Giorgi A., Lizzi A. R., Luzi C., Mignogna G., Bozzi A., Schinina M. E.   +7 more
openaire   +2 more sources

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia

Cell Death Discovery, 2021
Internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3) confers poor prognosis and is found in approximately 25% of cases of acute myeloid leukemia (AML).
Sivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, Souichi Takasugi, Ayano Nakamura, Miyuki Takahashi, Kaori Uchino, Satsuki Murakami, Md Wahiduzzaman, Lam Quang Vu, Md Lutfur Rahman, Muhammad Nazmul Hasan, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Kazuhiro Yoshikawa, Susumu Suzuki, Ryuzo Ueda, Masayuki Ejiri, Yoshitaka Hosokawa, Akiyoshi Takami   +20 more
doaj   +1 more source

Tendency of K562 Chronic Myeloid Leukemia Cells Towards Cell Reprogramming

Turkish Journal of Hematology, 2018
Objective: Cancer cell reprogramming is a potential tool to study cancer progression, disease pathology, and drug sensitivity. Prior to performing cancer reprogramming studies, it is important to evaluate the stemness predisposition of cells that will be
Açelya Yılmazer Aktuna
doaj   +1 more source